New Delhi: External Affairs Minister S Jaishankar is on a five-day official visit to the United States starting today till May 28. He began his official tour by visiting New York on Monday after India entered the United Security Council on January 1, 2021.
During his stay in the United States, EAM is expected to discuss COVID-19 which tops his agenda as well as other related healthcare issues. Besides that, an entire range of international and regional issues such as Afghanistan as well as the deepening of bilateral relationships between India and the United States will be discussed.
Significance of his visit
Jaishankar’s visit comes at a time when India is battling the deadly wave of coronavirus and the healthcare system is sinking as the country reels under shortage of vaccines, life-gasping oxygen and other healthcare aid. And also his visit is the first in-person after Biden took over as the President of the United States.
Meanwhile, as many countries have come forward to help India in its fight against the second wave of the pandemic, Delhi is engaged with the United States administration in the procurement and manufacturing of the vaccines, which is expected to ease out the vaccination drive in the country.
Therefore, Jaishankar’s visit will focus on vaccine production which is going to set forth the strong vaccine diplomacy between the two nations, considered necessary as the pandemic hits the world hard.
Read:Delhi govt preparing for third wave of COVID, assures Kejriwal
Speaking to ETV Bharat, Former Ambassador Ashok Sajjanhar said, "Jaishankar’s visit is relevant also because there is a very rapid change that is taking place in the geopolitical circumstances. It comes after the first Quad summit that took place on 12 March and also his visit comes after the very strong support that the United States has displayed to deal with the pandemic in India. Therefore, his visit is basically to further strengthen the cooperation and find additional avenues and areas, where we can work together."
"There are going to be three issues that will be discussed during his visit –Firstly, in terms of the waiver of the Defense Production Act, second is in terms of supply chain issue-raw materials required by Indian companies for vaccine production and the third is in terms of TRIP's waiver at the WTO. American’s say that the waiving of patent rights should be for 16-18 months, whereas India says it would be for three years, on the other hand, India has a much broader demand list of medical equipment, in addition to the vaccines. These are some of the pressing issues even with the United States and this will be the topic of discussion”, he pointed.
India-US bonhomie